Crescent Biopharma

13 open jobs

• Director, Talent Acquisition

  Crescent Biopharma · Waltham, MA onsite director

  Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. By

  Applyto Director, Talent Acquisition at Crescent Biopharma seen live 1 day ago posted 3 days ago

• Executive Director/Vice President, Corporate Development

  Crescent Biopharma · Waltham, MA onsite vp

  Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. By

  Applyto Executive Director/Vice President, Corporate Development at Crescent Biopharma seen live 1 day ago posted 45 days ago

• Director, ADC Drug Substance

  Crescent Biopharma · Waltham, MA onsite director

  Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. By

  Applyto Director, ADC Drug Substance at Crescent Biopharma seen live 1 day ago posted 53 days ago

• Director/Senior Director, Drug Product

  Crescent Biopharma · Waltham, MA onsite director

  Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. By

  Applyto Director/Senior Director, Drug Product at Crescent Biopharma seen live 1 day ago posted 53 days ago

• Executive Assistant - R&D

  Crescent Biopharma · Waltham, MA onsite

  Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. By

  Applyto Executive Assistant - R&D at Crescent Biopharma seen live 1 day ago posted 67 days ago

• Director/Senior Director, GMP Quality Assurance Operations

  Crescent Biopharma · Waltham, MA onsite director

  Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. By

  Applyto Director/Senior Director, GMP Quality Assurance Operations at Crescent Biopharma seen live 1 day ago posted 69 days ago

• Director/Senior Director, QMS, Digital QA and GxP Compliance

  Crescent Biopharma · Waltham, MA onsite director

  Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. By

  Applyto Director/Senior Director, QMS, Digital QA and GxP Compliance at Crescent Biopharma seen live 1 day ago posted 69 days ago

• Manager, CMC Project Management

  Crescent Biopharma · Waltham, MA onsite manager $140k – $180k / year

  Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. By

  Applyto Manager, CMC Project Management at Crescent Biopharma seen live 1 day ago posted 76 days ago

• Vice President, Biostatistics

  Crescent Biopharma · Waltham, MA onsite vp $323k – $357k / year

  Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. By

  Applyto Vice President, Biostatistics at Crescent Biopharma seen live 1 day ago posted 88 days ago

• Vice President, Pharmacovigilance

  Crescent Biopharma · Waltham, MA onsite vp $323k – $357k / year

  Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. By

  Applyto Vice President, Pharmacovigilance at Crescent Biopharma seen live 1 day ago posted 88 days ago

• Vice President, Program Team Leader

  Crescent Biopharma · Waltham, MA onsite vp $323k – $357k / year

  Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. By

  Applyto Vice President, Program Team Leader at Crescent Biopharma seen live 1 day ago posted 105 days ago

• Executive Director, Regulatory Affairs CMC

  Crescent Biopharma · Waltham, MA onsite director

  Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. By

  Applyto Executive Director, Regulatory Affairs CMC at Crescent Biopharma seen live 1 day ago posted 129 days ago

• Executive Director/Vice President, Medical Lead

  Crescent Biopharma · Waltham, MA onsite vp $330k – $365k / year

  Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. By

  Applyto Executive Director/Vice President, Medical Lead at Crescent Biopharma seen live 1 day ago posted 341 days ago